Sun Pharma faced a setback as SCD-044, a drug under Phase-2 trial for atopic dermatitis and psoriasis, failed to meet the efficacy endpoint. Despite passing Phase-1 safety evaluation, the molecule did not achieve the required improvement in PASI and EASI scores at week 16. This outcome is significant as it impacts Sun Pharma’s pipeline and competitive position in the pharma market, especially in the lucrative auto-immune drug segment dominated by big pharma companies.
Read more from thehindubusinessline.com
